Implication of transcriptional repression in compound C-induced apoptosis in cancer cells

RY Dai1,2,3,7, XF Zhao2,4,7, JJ Li2,7, R Chen2, ZL Luo2, LX Yu2, SK Chen1, CY Zhang1, CY Duan1, YP Liu1, CH Feng3, XM Xia3, H Li1, J Fu1,2 and HY Wang1,2,6

Compound C, a well-known inhibitor of AMP-activated protein kinase (AMPK), has been reported to induce apoptosis in some types of cells. However, the underlying mechanisms remain largely unclear. Using a DNA microarray analysis, we found that the expression of many genes was downregulated upon treatment with compound C. Importantly, compound C caused transcriptional repression with the induction of p53, a well-known marker of transcriptional stress response, in several cancer cell lines. Compound C did not induce the phosphorylation of p53 but dramatically increased the protein level of p53 similar to other transcriptional inhibitors, including 5,6-dichloro-1-β-D-ribobenzimidazole (DRB). Consistent with previous reports, we found that compound C initiated apoptotic death of cancer cells in an AMPK-independent manner. Similar to DRB and actinomycin D (ActD), two classic transcription inhibitors, compound C not only resulted in the loss of Bcl-2 and Bcl-xl protein but also induced the phosphorylation of eukaryotic initiation factor-alpha (eIF2α) on Ser51. Hence, the phosphorylation of eIF2α might be a novel marker of transcriptional inhibition. It is noteworthy that compound C-mediated apoptosis of cancer cells is correlated with decreased expression of Bcl-2 and Bcl-xl and the phosphorylation of eIF2α on Ser51. Remarkably, compound C exhibits potent anticancer activities in vivo. Taken together, our data suggest that compound C may be an attractive candidate for anticancer drug development.

Cell Death and Disease (2013) 4, e883; doi:10.1038/cddis.2013.419; published online 24 October 2013

Subject Category: Cancer

Finding therapies that target and kill cancer cells is a major goal of most cancer therapeutic approaches. Several cell death modalities, including programmed cell death, necrosis and mitotic catastrophe can initiate cancer cells death.1–5 Irradiation and mitotic catastrophe can initiate apoptosis.4,11,12 Transcriptional inhibitors induce apoptosis by both p53-dependent or -independent mechanisms.11 Importantly, transformed cells appear to be more sensitive to transcriptional stress induced by disruption of RNA synthesis than normal cells.12,16 General transcriptional inhibitors may be useful in cancer therapies and, in some instances, have been shown to work as antiviral agents.13,17 Some of these drugs, such as flavopiridol and seliciclib, are potential drugs against different types of cancer.18–23

AMP-activated protein kinase (AMPK) is a principal intracellular energy sensor, which has an essential role as a master regulator of cellular energy homeostasis. AMPK is activated by an increasing cellular AMP/ATP ratio caused by metabolic stresses that interfere with ATP production or that accelerate ATP consumption.24–29 AMPK maintains the energy balance through the direct phosphorylation of target proteins or via transcriptional control of target genes.30,31

OPEN
Compound C, also known as dorsomorphin, has been described as a pharmacological AMPK inhibitor that efficiently blocks metabolic actions of AMPK.\textsuperscript{32} It has been reported that compound C attenuates the apoptotic activities of AMPK in various cell types.\textsuperscript{33–39} In contrast, it has also been suggested that compound C treatment directly causes apoptosis in some cancer cells, including breast cancer cells and skin cancer cells.\textsuperscript{40–43}

In this study, we investigated the potential association between compound C and apoptosis in different cancer cells. We demonstrated that compound C is a potent apoptosis inducer in various cancer cells. Interestingly, compound C initiates transcriptional inhibition and p53 induction in cancer cells. Further, we found that compound C-mediated apoptosis is associated with the decreased expression of Bcl-2 and Bcl-xl, and the phosphorylation of eIF2α. Importantly, compound C exhibits potent anticancer activities in vivo.

### Results

**Compound C initiates apoptosis in cancer cells.** To investigate the potential role of compound C in the induction of apoptosis in cancer cells, we first examined the proapoptotic effects of compound C in A549, SMMC-7721 and HeLa cells. Western blot analysis revealed that compound C treatment induced the cleavage of PARP and caspase-3 in A549, SMMC-7721 and HeLa cells in a concentration-dependent manner (Figure 1a). Moreover, compound C resulted in the activation of caspase-3 and PARP cleavage in A549, SMMC-7721 and HeLa cells in a time-dependent manner (Figure 1b). The effects of compound C on apoptosis induction in cancer cells in a concentration- and time-dependent manner were reconfirmed by annexin V-FITC apoptosis analysis (Figures 1c and d). Importantly, compound C-mediated apoptosis was obviously inhibited by the pretreatment of z-VAD-fmk, a specific inhibitor of caspase (Figure 1e). Thus, compound C induces apoptosis in a caspase-dependent manner.

To make sure whether inhibition of AMPK is involved in compound C-mediated apoptosis, specific small-interfering RNA (siRNA) was used to block the expression of MAPKα. The results showed that AMPKα knockdown had no evident effects on compound C-mediated apoptosis in A549, SMMC-7721 and HeLa cells (Supplementary Figure 1). Taken together, these data suggest that compound C initiates apoptosis of cancer cells in an AMPK-independent manner.

**Compound C inhibits transcription in cancer cells.** To identify the molecules involved in the proapoptotic activities of compound C, we compared the gene expression profiles of compound C-treated A549 cells with physiological saline-treated A549 cells using microarray analysis. Using a DNA microarray, we analyzed about 32,000 genes for changes in expression upon compound C treatment. Statistical analysis indicated that 6030 genes had a significant change in expression levels, of which 5713 (17.85% of total genes) and 317 (0.99% of total genes) were more than twofold down- or upregulated (Figure 2a). We tested some of the downregulated genes, such as...
hepatocyte growth factor receptor (c-Met), epidermal growth factor receptor (EGFR) and proliferating cell nuclear antigen (PCNA), using real-time RT-PCR analysis. The results reconfirmed that c-Met, EGFR and PCNA were downregulated in A549, SMMC-7721 and HeLa cells after compound C treatment for 24 h (Figure 2b).

To investigate the impact of compound C on transcription, mRNA synthesis was measured in compound C-treated cancer cells in the presence of \([3H]\)uridine. It is noteworthy that compound C inhibited mRNA synthesis in a concentration-dependent manner in A549, SMMC-7721 and HeLa cells (Figure 3a), indicating that compound C inhibits transcription in cancer cells. As endoplasmic reticulum stress (ER stress) activation can induce the expression of specific mRNA, such as 78 kDa glucose-regulated protein (GRP78) mRNA, the impact of compound C on ER stress-induced GRP78 mRNA synthesis was tested. Importantly, compound C treatment not only decreased GRP78 mRNA but also blocked ER stress inducers tunicamycin (Tun)- and thapsigargin (Tg)-induced GRP78 mRNA synthesis in A549, SMMC-7721 and HeLa cells (Figure 3b). These results reconfirm the function of transcriptional inhibition of compound C. Further, compound C induced the downregulation of EGFR mRNA, which is not regulated by ER stress, under ER stress conditions (Figure 3c), suggesting that the effects of compound C on ER stress-induced transcription inhibition is nonspecific.

As p53 is one of the hallmarks of global transcriptional repression, it is reasonable to suggest that compound C might initiate the induction of p53. This notion is supported by the data that compound C resulted in the accumulation of p53 in A549, SMMC-7721 and HeLa cells (Figure 3d). In line with DRB, compound C induced the accumulation of p53 proteins that lacks evident phosphorylation on Ser15 site (Figure 3e). However, ActD efficiently initiated the phosphorylation of p53 on Ser15 (Figure 3e). Taken together, these data indicate that compound C is a potent suppressor of transcription.

Bcl-2 and Bcl-xl downregulation promotes compound C-induced apoptosis in cancer cells. As transcriptional stress can initiate cell apoptosis in a p53-dependent or p53-independent manner, we assessed whether p53 is involved in compound C-mediated apoptosis in cancer cells. It is noteworthy that p53 inhibitor PFT-α pretreatment had no demonstrable effects on compound C-mediated apoptosis in A549 and SMMC-7721 cells (Figure 4a). Further, suppression of p53 expression also had no evident effects on compound C-mediated apoptosis (Figure 4b). These data indicate that p53 is not involved in compound C-mediated apoptosis in cancer cells.

As Bcl-2 and Bcl-xl are essential for inhibiting the activation of caspases, we investigated whether Bcl-2 and Bcl-xl are involved in compound C-mediated apoptosis. The expression of Bcl-2 and Bcl-xl in compound C-treated cancer cells was examined. As shown in Figure 5a, compound C decreased the protein levels of Bcl-2 and Bcl-xl in a time-dependent manner. More importantly, Bcl-2 and Bcl-xl inhibitor ABT-263 preincubation promoted compound C-induced apoptosis in A549, SMMC-7721 and HeLa cells (Figure 5b). Further, transcriptional inhibitors ActD and DRB also induced Bcl-2 and Bcl-xl decreasing in A549 and SMMC-7721 cells (Figure 5c), indicating that the loss of Bcl-2 and Bcl-xl promotes transcriptional inhibition-mediated apoptosis. Together, these findings indicate that the compound C-mediated decreasing of Bcl-2 and Bcl-xl is involved partially in the apoptosis of cancer cells under compound C-induced transcriptional stress.

The phosphorylation of eIF2α promotes compound C-induced apoptosis in cancer cells. It is known that the eIF2α pathway, a critical pathway that regulates the integrated stress response, can be activated by various stress stimuli. We therefore studied whether compound C regulates the eIF2α pathway in cancer cells. We found that compound C induced the phosphorylation of eIF2α on Ser51
in a dose- and time-dependent manner (Figures 6a and b), indicating the eIF2α pathway is implicated in compound C-induced transcriptional stress response. To further test the role of the eIF2α pathway in transcriptional stress response, we investigated the phosphorylation of eIF2α on Ser51 upon ActD or DRB treatment. The data showed that ActD and DRB induced the phosphorylation of eIF2α on Ser51 in A549, SMMC-7721 and HeLa cells (Figure 6c), indicating that transcriptional stress activates the eIF2α pathway.

To make sure whether the phosphorylation of eIF2α has a role in compound C-induced apoptosis, salubrinal, a selective inhibitor of eIF2α dephosphorylation, was used in our study.
As depicted in Figure 6d, salubrinal pretreatment promoted A549, SMMC-7721 and HeLa cells apoptosis upon compound C treatment. Further, transfection of A549, SMMC-7721 and HeLa cells with the phosphorylation-mutant expression plasmid eIF2α-S51A, which inhibits the phosphorylation of eIF2α on Ser51, inhibited compound C-mediated apoptosis (Figure 6e). Taken together, these results suggest the phosphorylation of eIF2α is involved in part in the apoptosis of cancer cells under compound C-mediated transcriptional stress.

**Compound C suppresses growth of cancer cells in mice.** We assessed the potential of compound C in inhibition of tumor formation using an in vivo mouse model. The subcutaneous tumor model was chosen in our experiments for its high implant survival rate and ease in separating tumor from host tissue for accurate measurements of tumor growth. Treatment with compound C significantly reduced tumor burden of A549 and SMMC-7721 cells as compared with the control group (Figures 7a and b). These data demonstrated that compound C suppresses the growth of cancer cells in xenograft mouse models, which imply a potential use of compound C in repressing the progression of cancer cells.

**Discussion**

Although compound C is implicated in the induction of apoptosis, it remains largely unclear how compound C exerts its proapoptotic action. The present work reveals that compound C represses transcription and initiates apoptosis in
cancer cells partially by decreasing the expression of Bcl-2 and Bcl-xl, and by inducing the phosphorylation of eIF2α.

It has been suggested that compound C induces apoptosis in some types of cells.⁴⁰–⁴³ In agreement with these reports, we saw a similar effect in several cancer cell lines upon treatment with compound C. On the basis of the data that blocking AMPKα had no effects on compound C-induced apoptosis, we suggest compound C induces apoptosis in an AMPK-independent manner in cancer cells. As compound C induces autophagy through AMPK inhibition-independent mechanisms,⁵⁶ it is necessary to address whether the induction of autophagy is involved in apoptosis of cancer cells upon compound C treatment. Compound C induced autophagy in A549 and HeLa cells (Supplementary Figure 2a), but the activation of autophagy was not responsible for compound C-mediated apoptosis (Supplementary Figure 2b). Apoptosis in mammalian cells is a multistep process that results in the activation of caspases, followed by execution of cell death. We found that compound C-induced apoptosis is caspase dependent.

A noteworthy property of compound C is its ability to inhibit transcription in various cancer cells. A recent report indicated that compound C inhibits ER stress-induced transcription program depending on the glucose deprivation conditions through a mechanism independent of AMPK.⁵⁷ However, our data indicate that compound C blocks ER stress-induced transcription through nonspecific transcriptional blockade. A striking feature of compound C-mediated apoptosis is that it is p53 independent. We have shown that A549, SMMC-7721 and HeLa cells along with their p53 inhibition or knockdown undergo apoptosis to the same extent upon treatment with compound C. This is in agreement with the observation that p53 is a marker but not a mediator of transcriptional inhibitors ARC- and flavopiridol-induced apoptosis.¹⁰,⁴⁸ However, some...
of other transcriptional inhibitors, such as DRB and α-amanitin, were suggested to induce p53-dependent apoptosis. It was shown recently that p53 knockdown cancer cells were much more resistant to compound C-induced apoptosis. In our study, however, although the accumulation of p53 was observed in response to compound C treatment, it did not lead to enhanced apoptosis. The reason for this discrepancy is unclear. The differences in the cell lines or experimental approaches used in studies could be the reason behind the difference in outcome.

An important question now before us is how compound C induces apoptosis under transcription stress conditions. On the basis of our findings that compound C resulted in Bcl-2 and Bcl-xl decrease, we propose that Bcl-2 and Bcl-xl might be involved in compound C-mediated apoptosis. This speculation was demonstrated by the findings that blocking the function of Bcl-2 and Bcl-xl promoted compound C-induced apoptosis. In our case, it is reasonable to speculate that the ability of compound C to downregulate antiapoptotic proteins, including Bcl-2 and Bcl-xl, has an important role in transcription repression-induced apoptosis upon treatment with compound C.

As compound C induced the phosphorylation on Ser51 of eIF2α, which is an important regulator of the decision between survival and apoptosis in response to diverse stress, we focused on the role of eIF2α signaling in regulating compound C-mediated apoptosis. As salubrinal, the selective inhibitor of eIF2α dephosphorylation, pretreatment promoted cancer cells apoptosis upon compound C treatment, it is reasonable to suggest that the phosphorylation of eIF2α contributed to compound C-induced apoptosis. This is further supported by the observation that blocking the phosphorylation of eIF2α by the phosphorylation-mutant expression plasmid eIF2αS51A inhibited compound C-induced apoptosis. Interestingly, other transcriptional inhibitors, including ActD and DRB, also induced the phosphorylation of eIF2α on Ser51, indicating that the eIF2α pathway is an important regulator of transcriptional stress. The fact that compound C repressed tumor growth in mice models makes a strong case for consideration of compound C as a potential anticancer agent. Hence, compound C could be a promising candidate for in vivo studies.

In brief, the present work reveals that transcriptional repression has an essential role in compound C-induced apoptosis in cancer cells. The ability of compound C to inhibit tumor growth in vivo implies its potent anticancer activities. More detailed studies on the function of compound C upon transcriptional repression will contribute to the development of compound C as anticancer drug.

Materials and Methods

Chemicals and antibodies. AMPK inhibitor compound C, eIF2α phosphatase enzymes inhibitor salubrinal and autophagy inhibitor bafilomycin A1 were purchased from Tocris Bioscience (Bristol, UK). Transcriptional inhibitors DRB and ActD, p53 inhibitor PFT-α, caspase inhibitor z-VAD-fmk and ER stress inducers Tg and Tun were purchased from Sigma (Lyon, France). Bcl-2 and Bcl-xl inhibitor ABT-263 was purchased from Selleck Chemicals (Houston, TX, USA). GFP siRNA, p53 siRNA, AMPKα siRNA and antibodies against eIF2α and β-actin were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Antibodies

Figure 7 Compound C suppresses growth of cancer cells in mice. (a and b) After mice were subcutaneously inoculated with 1 × 10⁷ A549 (a) or SMMC-7721 (b) cells for 7 days, intratumoral injection was performed to the experimental group mice with 15 mg/kg compound C twice weekly. The control group mice were treated by direct intratumoral injection of physiological saline twice weekly. Representative subcutaneous tumors are shown (left panel). Tumor size was measured every 3 days from day 6 (a) or 9 (b) through days 24 (a) or 27 (b) after inoculation of A549 (a) or SMMC-7721 (b) cells into mice (right panel). Error bars stand for S.D. of six animals.
against phospho-eIF2α (Ser51), phospho-p53 (Ser15), AMPKα, p53, Bcl-2, Bcl-xl, PARP, cleaved caspase-3 and LC3A/B were purchased from Cell Signaling Technology (Danvers, MA, USA). eIF2αS51A plasmid was purchased from Addgene (Cambridge, MA, USA).

Cell culture and treatments. Human lung adenocarcinoma epithelial cell line A549, human hepatocellular carcinoma cell line HCC-MC-7 and human cervical cancer cell line HeLa were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin in a humidified incubator containing 5% CO2 and 95% ambient air at 37 °C. The protocol used for p53 and AMPKα knockdown has been previously described.59 Transfection of vectors for the expression of GFP and eIF2αS51A, which lacks the phosphorylation site, were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s manual.

Western blot analysis. Cells were lysed in Triton x-100 buffer (20 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM PMSF, 10 mM sodium fluoride, 5 mM/gm of aprotinin, 20 mM leupeptin and 1 mM sodium orthovanadate) and centrifuged at 12 000 × g for 15 min. Protein concentrations were measured using the BCA assay. Protein samples were denatured with 4 × SDS-loading buffer (200 mM Tris, pH 6.8, 8% SDS, 400 mM DTT, 0.4% bromphenol blue and 40% glycerol) at 100 °C for 5 min and subjected to standard SDS-PAGE and western blot analysis as previously described.

Apoplosis analysis. Apoptosis was detected using the annexin V-FITC apoptosis detection kit (Invitrogen) according to the manufacturer’s manual. Annexin V staining was analyzed by flow cytometry within 1 h. The experiments were repeated three times.

Reverse transcription reaction and real-time PCR. Total RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer’s instructions. The reverse transcription reactions were carried out using the M-MLV reverse transcriptase (Promega, Madison, WI, USA) according to the manufacturer’s protocol. Real-time PCR analyses were performed using SYBR Premix Ex Taq (Takara, Tokyo, Japan). Results were normalized with 18S. The primers used in this study are shown in Supplementary Table 1.

Thymidine incorporation. Cells (1–2 × 105 per well) were grown overnight and treated with 10 μM compound C for the experimental wells or physiological saline for the control wells in medium containing 0.5% FBS. After 24 h, the cells were pulsed with [3H]thymidine (1 μCi per well) for 6 h, and then fixed with 5% trichloroacetic acid and solubilized before scintillation counting. Experiments were repeated three times.

RNA isolation and microarray analysis. Total RNA was extracted from cells using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Fluorescent aRNA targets were prepared from 2.5 μg total RNA samples using OneArray Amino Allyl aRNA Amplification Kit (Phalanx Biotech Group, Hsinchu, Taiwan) and Cy5 dyes (Amersham Pharmacia, Piscataway, NJ, USA). Fluorescent targets were hybridized to the Human Whole Genome OneArray with Phalanx hybridization buffer using Phalanx Hybridization System. After 16 h hybridization at 50 °C, non-specific binding targets were washed away by three different washing steps (wash I, 42 °C for 5 min; Wash II, 42 °C for 5 min, 25 °C for 5 min; Wash III, rinse 20 times) and the slides were dried by centrifugation and scanned by Axon 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). The intensities of each probe were obtained by GenePix 4.1 software (Molecular Devices).

Tumor xenograft experiments. The use of animals in present study has been approved by the local committee on animal care. Six-week-old NOD/SCID nude mice were purchased from the Shanghai Experimental Center (CBA, Shanghai, China). Mice were subcutaneously inoculated with A549 or HCC-MC-7/721 cells. Approximately 1 × 107 cells in 0.2 ml culture medium containing phosphate-buffered saline were injected subcutaneously into the right flank of the mice, which were then observed daily for signs of tumor development. Tumor volume was calculated as below: V (cm3) = width2 (cm) × length (cm)/2. Seven days after inoculation, mice were randomly divided into two groups (n = 6). Intratumoral injection was performed to the experimental group mice with 15 mg/kg compound C (compound C were dissolved in physiological saline) twice weekly. The control group mice were treated by direct intratumoral injection of physiological saline twice weekly.

Immunofluorescence staining and confocal microscopy analysis. Cells were replated on chamber slides. When cultured to 60% confluence, cells that were incubated with anti-LC3A/B antibodies conjugated to CY3 (Invitrogen) for immunofluorescence and confocal microscopy assay.

Statistical analysis. Results were expressed as the mean ± S.D. Statistical analysis was performed using Student’s t-test. P < 0.05 was considered statistically significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was supported by grants from Sichuan Province Science Foundation for Youths (2013JQ0045), the National Natural Science Foundation of China (81008886, 81221061, 81101174, 91209732, 91229201), New Century Excellent Talents in University Grant (NCET-11-1058), State Key Project for Infectious Diseases (2012ZX10002-009, 011), and Key Project of Army (BWS11J030).

1. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231–237.
2. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bharadwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423–434.
3. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13: 7271–7279.
4. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16: 663–669.
5. Kono K, Mimura K, Kiesling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis 2013; 4: e688.
6. Berger I, Blanco AG, Boelens R, Cavarelli J, Coll M, Folkins GE et al. Structural insights into transcription complexes. J Struct Biol 2011; 175: 135–146.
7. Kornberg RD. The molecular basis of eukaryotic transcription. Cell Death Differ 2007; 14: 1989–1997.
8. Boeger H, Buschell DA, Davis R, Griesenbeck J, Lorch Y, Stratann JS et al. Structural basis of eukaryotic gene transcription. FEBS Lett 2005; 579: 899–903.
9. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavipiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513–2519.
10. Radakhrishnan SK, Gartel AL. A novel translocation inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 2008; 68: 3264–3270.
11. Gartel AL. Transcriptional inhibitors, p53 and apoptosis. Biochem Biophys Acta 2008; 1786: 83–86.
12. Derheimer FA, Chang CW, Ljungman M. Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 2005; 41: 2569–2576.
13. Biagkoskylin MV. Flavipiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3: 1537–1542.
14. Radakhrishnan SK, Halai M, Bhat UG, Kurmasheva RT, Houghton PJ, Gartel AL. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene 2008; 27: 694–699.
15. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Gimenez MS et al. Mechanism and functional role of XIAP and Smac down-regulation in flavipiridol-induced autophagic-antiautophagic interactions. Mol Cancer Ther 2007; 6: 692–702.
16. Kounenis C, Giacca A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997; 17: 7306–7316.
17. Chao SH, Fujinaga K, Manon JE, Taube R, Sausville EA, Senderowicz AM et al. Flavipiridol inhibits P-TEFb and blocks H1-1 replication. J Biol Chem 2007; 282: 28345–28348.
18. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770–1783.
19. Benson C, White J, De Bono J, O’Donnell A, Raynau F, Cruickshank C et al. A phase II trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96: 29–37.
20. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavipiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012–6018.
Transcriptional repression property of compound C

RY Dai et al

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)